Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Type:
Grant
Filed:
September 23, 2022
Date of Patent:
June 20, 2023
Assignee:
AbbVie Inc.
Inventors:
Ayman Allian, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Thomas B. Borchardt
Abstract: The invention described herein relates to dosing methods for treating relapsed and refractory multiple myeloma (RRMM) in a human subject comprising administering to the subject venetoclax in combination with daratumumab and dexamethasone.
Type:
Application
Filed:
December 8, 2022
Publication date:
June 15, 2023
Applicant:
ABBVIE INC.
Inventors:
Orlando F. BUENO, Yan LUO, Laura Leanne FLEMING, Mohamed BADAWI, Ahmed Hamed SALEM
Abstract: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.
Type:
Application
Filed:
May 13, 2021
Publication date:
June 8, 2023
Applicants:
Disc Medicine, Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
Inventors:
Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, Jennifer M. Perez
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Type:
Grant
Filed:
September 23, 2022
Date of Patent:
May 30, 2023
Assignee:
AbbVie Inc.
Inventors:
Ayman Allian, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Thomas B. Borchardt
Abstract: A child-resistant medication container assembly that includes a blister card including a plurality of compartments each configured to support a dosage of medication, and a puck including a body portion, a recess that defines a partition wall in the body portion, and a plurality of openings defined in the partition wall. Each opening corresponds to one of the plurality of compartments in the blister card. The assembly further includes a carton including a first wall opposite a second wall. An access opening is defined in the first wall and a plurality of perforations are defined in the second wall. The access opening is sized to provide access to the plurality of compartments, and each perforation corresponds to one of the plurality of compartments in the blister card.
Type:
Grant
Filed:
May 13, 2021
Date of Patent:
May 16, 2023
Assignee:
ABBVIE INC.
Inventors:
Todd Marshall, Bhimaprasad Medhal, John G. Finch, Joy Elizabeth Borgardt
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Type:
Application
Filed:
October 7, 2022
Publication date:
May 11, 2023
Applicants:
AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
Inventors:
Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.
Abstract: The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
Type:
Application
Filed:
August 3, 2022
Publication date:
April 27, 2023
Applicant:
AbbVie Inc.
Inventors:
Alexandru DEAC, Ye HUANG, John M. LIPARI, Alexander RUGGLES, Thin Yu TUN
Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
Type:
Grant
Filed:
April 1, 2022
Date of Patent:
March 21, 2023
Assignee:
AbbVie Inc.
Inventors:
Ana Paula Machado De Lacerda, Jose Jeffrey V. Enejosa, Aileen L. Pangan, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Type:
Grant
Filed:
June 7, 2022
Date of Patent:
February 28, 2023
Assignees:
GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
Inventors:
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
Type:
Grant
Filed:
April 28, 2022
Date of Patent:
January 31, 2023
Assignee:
AbbVie Inc.
Inventors:
Aileen L. Pangan, Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado De Lacerda, Anne M. Robinson, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
Type:
Application
Filed:
September 15, 2022
Publication date:
January 26, 2023
Applicants:
GENENTECH, INC., ABBVIE INC.
Inventors:
Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
Type:
Application
Filed:
June 7, 2022
Publication date:
January 5, 2023
Applicants:
GENENTECH, INC., ABBVIE INC.
Inventors:
Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
Abstract: A system for fulfilling a prescription is provided. The system may include at least one processor programmed to (i) receive a prescription request including patient data relating to a patient, (ii) determine an insurance provider of the patient based on the received patient data, (iii) determine an insured cost for a prescription for the patient, (iv) determine a non-insured cost for the prescription for the patient, (v) compare the insured cost to the non-insured cost to determine which cost is lower, (vi) depending on which cost is lower, i) send a message to the patient with a corresponding recommendation, and ii) process an insurance claim and/or a payment transaction upon authorization from the patient, and (vii) transmit the prescription to a pharmacy for further processing.
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Type:
Grant
Filed:
May 27, 2022
Date of Patent:
December 27, 2022
Assignee:
AbbVie Inc.
Inventors:
Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Type:
Grant
Filed:
May 27, 2022
Date of Patent:
December 27, 2022
Assignee:
AbbVie Inc.
Inventors:
Ahmed A. Othman, Mohamed-Eslam F. Mohamed, Ben Klünder, Aileen L. Pangan
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Type:
Grant
Filed:
May 27, 2022
Date of Patent:
December 27, 2022
Assignee:
AbbVie Inc.
Inventors:
Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder